C. Nicolette

G. Sandford, D. Margolis, C. Nicolette, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma1

G. Linette, F. Haluska, F. Preffer, 2000, The Journal of Immunology.

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

R. Figlin, V. Master, M. Debenedette, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion

D. Calderhead, I. Tcherepanova, C. Nicolette, 2008, BMC Molecular Biology.

Patients with Melanoma T Cells in + HLA-A * 0201-Restricted CD 8 the Epitope Specificity of Antigen-Transduced Dendritic Cells Reveals In Vitro Priming with Adenovirus / gp 100

G. Linette, F. Haluska, F. Preffer, 2000 .

Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro

M. Debenedette, Mark A. DeBenedette, David M. Calderhead, 2011, Journal of immunotherapy.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

J. Routy, D. Margolis, D. Asmuth, 2016, Journal of acquired immune deficiency syndromes.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

J. Coffin, D. Margolis, N. Archin, 2017, AIDS research and human retroviruses.

The identification of clinically relevant markers and therapeutic targets.

C. Nicolette, Glenn A Miller, 2003, Drug discovery today.

Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma

W. Lowrance, R. Figlin, C. Wood, 2020, Clinical Cancer Research.

1137OInterim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

R. Figlin, C. Wood, V. Master, 2017 .

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

Reduced Chronic Lymphocyte Activation following Interferon Alpha Blockade during the Acute Phase of Simian Immunodeficiency Virus Infection in Rhesus Macaques

J. Billingsley, R. Sékaly, M. Cameron, 2018, Journal of Virology.

Multiplex RT-PCR Amplification of HIV Genes to Create a Completely Autologous DC-Based Immunotherapy for the Treatment of HIV Infection

D. Calderhead, Aijing Z. Starr, I. Tcherepanova, 2008, PloS one.

Title Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA : A randomized , double-blind , placebo-controlled clinical trial Permalink

J. Routy, D. Margolis, D. Asmuth, 2022 .

Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib.

R. Figlin, V. Master, M. Debenedette, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

R. Figlin, J. Holzbeierlein, R. Lance, 2010 .

Impact of Autologous Dendritic Cell Immunotherapy (Arcelis™) on B Cell Subsets in HIV-1-Infected Subjects Receiving Antiretroviral Therapy

J. Routy, R. Sékaly, B. Yassine-Diab, 2008 .

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma

M. Debenedette, A. Gamble, C. Nicolette, 2023, Human vaccines & immunotherapeutics.

Immunosuppression Involving Soluble CD83 Induces Tolerogenic Dendritic Cells That Prevent Cardiac Allograft Rejection

A. Steinkasserer, Hao Wang, Weihua Liu, 2010, Transplantation.

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

J. Routy, R. Sékaly, B. Yassine-Diab, 2010, Clinical immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

R. Figlin, W. Miller, V. Master, 2015, Journal of Immunotherapy for Cancer.

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

R. Figlin, C. Wood, M. Debenedette, 2018 .

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

R. Figlin, V. Master, M. Debenedette, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.